对人类CD39的反义,在炎症性肠道疾病中失调免疫代谢
Lina Zhang1,2, Cortney Cagle1, Du Hanh Nguyen1,3
1Department of Anesthesia, Critical Care and Pain Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
在炎症性肠病 (IBD) 中,缺陷的CD39水平与免疫细胞失衡有关. 在调节性T (Treg) 和T辅助17 (Th17) 细胞中向CD39-ASRNA恢复了免疫平衡,并降低了IBD活动.
科学领域:
- 免疫学 免疫学 免疫学
- 分子生物学分子生物学
- 代谢途径 代谢途径
背景情况:
- 在炎症性肠病 (IBD) 中,缺陷的CD39水平会破坏调节性T (Treg) 细胞和T辅助17 (Th17) 效应体之间的平衡.
- CD39启动ATP水解,产生腺,腺是组织平衡的关键代谢物.
- 一种内源性反感RNA (CD39-AS) 调节人类的CD39,并且在IBDTregs和Th17细胞中升高.
研究的目的:
- 研究CD39-AS对健康人和IBD患者Treg和Th17细胞的功能影响.
- 探索向IBD中的CD39-AS变异的治疗潜力.
主要方法:
- 在Tregs和Th17细胞中分析CD39-AS拼接变体.
- 在人类细胞和大肠炎的人性化小鼠模型中,Oligonucleotide介导的CD39-AS阻断.
- 评估细胞代谢 (葡萄糖运输,糖解,氧化反应,线粒体健康).
- 在体内评估免疫细胞的功能,稳定性和疾病活性.
主要成果:
- CD39-AS存在于Treg特异性和Th17特异性拼接变体中.
- 阻断Treg CD39-AS减少了葡萄糖运输和糖解,增强了Treg功能和IBD中的稳定性.
- 沉默Th17CD39-AS限制了氧化反应,改善了线粒体健康.
- 在体内给药CD39-AS向寡核酸减少了结肠炎活动,GLUT1表达,并改善了肠道CD4+淋巴细胞中的线粒体健康.
- 鉴定出HIF-1α和STAT3激活是IBD细胞中调节CD39-AS的机制.
结论:
- CD39-AS是Treg和Th17细胞代谢的关键调节者.
- 向CD39-AS变体通过恢复免疫代谢和Treg稳定性为IBD提供了潜在的治疗策略.
- 干扰CD39-AS或其上调通路可能有助于控制IBD的炎症和疾病进展.
更多相关视频
08:37Induction of Murine Intestinal Inflammation by Adoptive Transfer of Effector CD4+CD45RBhigh T Cells into Immunodeficient Mice
Published on: April 21, 2015
10:21Mechanistic Insight into the Development of TNBS-Mediated Intestinal Fibrosis and Evaluating the Inhibitory Effects of Rapamycin
Published on: September 12, 2019
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Experimental RNAi
Role Of Notch Signalling In Intestinal Stem Cell Renewal
Direct cell-to-cell contact is needed for the activation of Notch signaling. The signal is initiated when a notch ligand binds to a receptor on an adjacent cell, also...
siRNA - Small Interfering RNAs
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
